This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
AZNPositive Net Change GILDNegative Net Change VRTXNegative Net Change INCYNegative Net Change MRNAPositive Net Change
biotechs
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.
BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS is set up for Q4 earnings beat, fueled by strong international companion animal products sales, even as weaker U.S. demand weighs on results.
MRNAPositive Net Change ZTSPositive Net Change CRSPNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?
by Ahan Chakraborty
NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change HIMSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.
MRKNegative Net Change MRNAPositive Net Change JAZZPositive Net Change CSTLPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
GSK Gets EU Approval for Expanded Use of Nucala in COPD
by Zacks Equity Research
GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.
GSKNegative Net Change ALKSNegative Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs
KOD Stock Up 24% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.
ALKSNegative Net Change ASRTNegative Net Change KODNegative Net Change CSTLPositive Net Change
biotechs
BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View
by Zacks Equity Research
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
BIIBNegative Net Change RHHBYNegative Net Change SUPNNegative Net Change
biotechs earnings medical pharmaceuticals
Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study
by Zacks Equity Research
Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.
JNJNegative Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill
by Ekta Bagri
HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal pushback.
NVONegative Net Change LLYNegative Net Change HIMSNegative Net Change
biotechnology biotechs medical pharmaceuticals